Cancer<\/p>\n
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) specialist that is advancing a novel and more potent class of payload. With the first two programs due to enter clinical development before the end of the year, the Swiss pharma also will pay up to $400 million more in potential milestones. The centerpiece of the deal is London-based Myricx\u2019s N-myristoyltransferase inhibitors, which in preclinical testing have prompted complete and durable tumor regression at well-tolerated doses in a range of solid tumors.<\/p>\n
BioWorld Science<\/a> Deals and M&A<\/a> Cancer<\/a> Antibody-drug conjugate<\/a> Europe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Cancer Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug…\n","protected":false},"author":2,"featured_media":99773,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[434,6261,8086,49362,2112,8568,197,48850,48852,206,1078,2349,48853,48851],"class_list":["post-99772","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-abbvie-inc","tag-antibody-drug-conjugate","tag-bioworld","tag-bioworld-science","tag-cancer","tag-deals-and-ma","tag-europe","tag-myricx-bio-ltd","tag-n-myristoyltransferase-inhibitors","tag-novartis","tag-novartis-ag","tag-pfizer-inc","tag-seagen-inc","tag-topoisomerases"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116884140676462379","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/99772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=99772"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/99772\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/99773"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=99772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=99772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=99772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}